These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31807017)

  • 1. Linc00511 Indicates A Poor Prognosis Of Liver Hepatocellular Carcinoma.
    Hu P; Cui H; Lei T; Li S; Mai E; Jia F
    Onco Targets Ther; 2019; 12():9367-9376. PubMed ID: 31807017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased long noncoding RNA LINC00511 is correlated with poor prognosis and contributes to cell proliferation and metastasis by modulating miR-424 in hepatocellular carcinoma.
    Wang RP; Jiang J; Jiang T; Wang Y; Chen LX
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3291-3301. PubMed ID: 31081082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LINC00511 as a ceRNA promotes cell malignant behaviors and correlates with prognosis of hepatocellular carcinoma patients by modulating miR-195/EYA1 axis.
    Hu WY; Wei HY; Li KM; Wang RB; Xu XQ; Feng R
    Biomed Pharmacother; 2020 Jan; 121():109642. PubMed ID: 31731191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMMD2 Upregulation Mediated by an ncRNA Axis Correlates With an Unfavorable Prognosis and Tumor Immune Infiltration in Liver Hepatocellular Carcinoma.
    Fang W; Gan Y; Zhang L; Xiong J
    Front Oncol; 2022; 12():853026. PubMed ID: 35574298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1.
    Zhu FY; Zhang SR; Wang LH; Wu WD; Zhao H
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8377-8390. PubMed ID: 31646568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis.
    Zhang H; Zhao B; Wang X; Zhang F; Yu W
    Life Sci; 2019 Jul; 228():135-144. PubMed ID: 31047896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA LINC00511 promoted cell proliferation and invasion via regulating miR-124-3p/EZH2 pathway in gastric cancer.
    Huang HG; Tang XL; Huang XS; Zhou L; Hao YG; Zheng YF
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4232-4245. PubMed ID: 32373959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long non-coding RNA LINC00511 regulates the expression of microRNA-625-5p and activates signal transducers and activators of transcription 3 (STAT3) to accelerate the progression of gastric cancer.
    Cui N; Sun Q; Liu H; Li L; Guo X; Shi Y; Jing C; Qin C; Zhao Y
    Bioengineered; 2021 Dec; 12(1):2915-2927. PubMed ID: 34224294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of
    Zheng R; Zhu HL; Hu BR; Ruan XJ; Cai HJ
    World J Clin Cases; 2020 Jul; 8(14):2917-2929. PubMed ID: 32775374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
    Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
    Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LINC00511 interacts with miR-765 and modulates tongue squamous cell carcinoma progression by targeting LAMC2.
    Ding J; Yang C; Yang S
    J Oral Pathol Med; 2018 May; 47(5):468-476. PubMed ID: 29315846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LINC00511 can promote the proliferation, migration and invasion of esophageal cancer cells through regulating microRNA-150-5p.
    Han D; Yuan RX; Su F
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2462-2469. PubMed ID: 32196597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TPM4 aggravates the malignant progression of hepatocellular carcinoma through negatively regulating SUSD2.
    Sheng ZG; Chen MH
    Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4756-4765. PubMed ID: 32432739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulated miRNA-22-3p promotes the progression and leads to poor prognosis of hepatocellular carcinoma through targeting CDKN2C.
    Kong D; Wang X; Wang X; Wang Z; Wang F
    J BUON; 2021; 26(2):409-417. PubMed ID: 34076987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-566 protects the malignant progression of breast cancer by negatively regulating WNT6.
    Zhao MC; Zhang MM; Li T; Tao ZH; Du YQ; Wang LP; Zhang J; Wang BY; Hu XC
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6185-6194. PubMed ID: 32572884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circular RNA circGFRA1 promotes angiogenesis, cell proliferation and migration of hepatocellular carcinoma by combining with miR-149.
    Yu YX; Ge TW; Zhang P
    Eur Rev Med Pharmacol Sci; 2020 Nov; 24(21):11058-11064. PubMed ID: 33215421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KLF5 promotes proliferation in gastric cancer via regulating p21 and CDK4.
    Chen P; Qian XK; Zhang YF; Sun XG; Shi XJ; Gao YS
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4224-4231. PubMed ID: 32373958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LINC00511 accelerates the proliferation of cardiomyocytes after myocardial ischemia/reperfusion injury by absorbing miRNA-515-5p.
    Zhang X; Liu MM; Guan MX; Li TT; Mei LL; Cong HL
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):2062-2069. PubMed ID: 32141575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lnc-LINC00511 promotes gastric cancer progression by regulating MiR-29c-3p/TRIP13 axis through AKT/mTOR pathway.
    Wu Y; Guo X; Jin L; Huang G; Niu L; Zhao Y
    Int J Biol Macromol; 2024 Oct; 281(Pt 3):136455. PubMed ID: 39389496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
    Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
    PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.